Switch theme
Sign up to access all valuation multiples
TaiMed Biologics Inc is a Taiwan-based biotechnology company. It is engaged in the discovery, development, and delivery of medicines for infectious disease. It capitalizes on its intellectual, extensive expertise, and management resources to develop a health-care product pipeline that benefits patients, rewards investors, and propels to prominence in the biotechnology industry. The company's products pipeline includes TMB-365, VRC07-523LS, and others. It earns revenue from sale of medicines and by providing contract testing and development services for biopharmaceuticals.
2007
n/a
LTM Revenue $19.0M
LTM EBITDA -$2.7M
$602M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
TaiMed Biologics has a last 12-month revenue of $19.0M and a last 12-month EBITDA of -$2.7M.
In the most recent fiscal year, TaiMed Biologics achieved revenue of $18.4M and an EBITDA of -$1.1M.
TaiMed Biologics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See TaiMed Biologics valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $14.8M | $18.4M | XXX | XXX | XXX |
| Gross Profit | $6.5M | $6.8M | XXX | XXX | XXX |
| Gross Margin | 44% | 37% | XXX | XXX | XXX |
| EBITDA | -$0.7M | -$1.1M | XXX | XXX | XXX |
| EBITDA Margin | -5% | -6% | XXX | XXX | XXX |
| Net Profit | -$8.1M | -$5.9M | XXX | XXX | XXX |
| Net Margin | -55% | -32% | XXX | XXX | XXX |
| Net Debt | $13.9M | $14.2M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, TaiMed Biologics's stock price is TWD 77 (or $2).
TaiMed Biologics has current market cap of TWD 21.1B (or $637M), and EV of TWD 19.9B (or $602M).
See TaiMed Biologics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $602M | $637M | XXX | XXX | XXX | XXX | $-0.02 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, TaiMed Biologics has market cap of $637M and EV of $602M.
TaiMed Biologics's trades at 31.7x LTM EV/Revenue multiple, and -225.4x LTM EBITDA.
Analysts estimate TaiMed Biologics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for TaiMed Biologics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $602M | XXX | XXX | XXX |
| EV/Revenue | 32.7x | XXX | XXX | XXX |
| EV/EBITDA | -570.9x | XXX | XXX | XXX |
| P/E | -104.5x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -50.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpTaiMed Biologics's NTM/LTM revenue growth is 9%
TaiMed Biologics's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, TaiMed Biologics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate TaiMed Biologics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for TaiMed Biologics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 24% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -6% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 42% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 3% | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 2% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 10% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 64% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 76% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
TaiMed Biologics acquired XXX companies to date.
Last acquisition by TaiMed Biologics was XXXXXXXX, XXXXX XXXXX XXXXXX . TaiMed Biologics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was TaiMed Biologics founded? | TaiMed Biologics was founded in 2007. |
| Where is TaiMed Biologics headquartered? | TaiMed Biologics is headquartered in Taiwan. |
| Is TaiMed Biologics publicy listed? | Yes, TaiMed Biologics is a public company listed on ROCO. |
| What is the stock symbol of TaiMed Biologics? | TaiMed Biologics trades under 4147 ticker. |
| When did TaiMed Biologics go public? | TaiMed Biologics went public in 2010. |
| Who are competitors of TaiMed Biologics? | Similar companies to TaiMed Biologics include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of TaiMed Biologics? | TaiMed Biologics's current market cap is $637M |
| What is the current revenue of TaiMed Biologics? | TaiMed Biologics's last 12-month revenue is $19.0M. |
| What is the current EBITDA of TaiMed Biologics? | TaiMed Biologics's last 12-month EBITDA is -$2.7M. |
| What is the current EV/Revenue multiple of TaiMed Biologics? | Current revenue multiple of TaiMed Biologics is 31.7x. |
| What is the current EV/EBITDA multiple of TaiMed Biologics? | Current EBITDA multiple of TaiMed Biologics is -225.4x. |
| What is the current revenue growth of TaiMed Biologics? | TaiMed Biologics revenue growth between 2023 and 2024 was 24%. |
| Is TaiMed Biologics profitable? | Yes, TaiMed Biologics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
